Those feared of capital raising, along with stop losses,...

Those feared of capital raising, along with stop losses, triggered today's sell-off. Unfortunately, I missed the opportunity at high 40s.

Cash as at 30 June 2024: $22m;
- R&D refund (usually receiving in October): should be around $10.9m (43.5% of the total R&D of $25.2m for the 2024 financial year);
- DXBO option exercising before 30 June 2025: $7.6m
Total available cash would be $40.5m

Total cash expenditures for last two financial years:
- 2023 financial year was $20m; and
- 2024 financial year was $28m.

Nina said the licensing deals (i.e US and China), will be signed before mid 2025.

The CR selloff is not justified, imo.